Top

Cancer Chemotherapy and Pharmacology

Published in:

01-11-2011 | Original Article

Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy

Authors: N. Cézé, G. Thibault, G. Goujon, J. Viguier, H. Watier, E. Dorval, T. Lecomte

Published in: Cancer Chemotherapy and Pharmacology | Issue 5/2011

Abstract

Background

Lymphopenia is a predictor of the efficacy and hematological toxicity of chemotherapy in various advanced cancers. There is little data about this relationship in colorectal cancer. In this retrospective study, the influence of pretreatment lymphopenia on hematological toxicity and the efficacy of chemotherapy was investigated in colorectal cancer patients.

Patients and methods

In total, 260 patients were included in the study. Correlations between pre-treatment lymphopenia (lymphocyte count < 1,000/μl) and the occurrence of hematological toxicity and efficacy of first-line palliative chemotherapy were investigated.

Results

Lymphopenia was found in 49/260 (19%) patients. Ten of these patients with lymphopenia (20.4%) experienced severe hematological toxicity compared with 17 of the remaining 211 (8%) patients (P = 0.01). Lymphopenia was identified as an independent factor for hematological toxicity. Among patients who received palliative chemotherapy, the objective response rate was significantly lower in lymphopenic patients than in the other patients (12.5% vs. 40.2%; P = 0.004). Lymphopenia was strongly associated with shorter progression-free survival (median 4 vs. 7 months; P = 0.033) and shorter overall survival (median 16 vs. 24 months, P = 0.024). Multivariate analysis revealed that lymphopenia had an independent effect on survival.

Conclusions

Our findings show that lymphopenia is an independent predictive factor for both hematological toxicity and efficacy of chemotherapy in colorectal cancer. Pre-treatment lymphocyte count may represent a simple and new predictive biomarker of chemotherapy effects in colorectal cancer patients.

Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef

Meyerhardt JA, Mayer RJ (2005) Systemic therapy for colorectal cancer. N Engl J Med 352:476–487PubMedCrossRef

Andre T, Boni C, Mounedji-Boudiaf L et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350:2343–2351PubMedCrossRef

Tang PA, Bentzen SM, Chen EX, Siu LL (2007) Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 25:4562–4568PubMedCrossRef

Kohne CH, Cunningham D, Di CF et al (2002) Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3,825 patients. Ann Oncol 13:308–317PubMedCrossRef

Freyer G, Rougier P, Bugat R et al (2000) Prognostic factors for tumour response, progression-free survival and toxicity in metastatic colorectal cancer patients given irinotecan (CPT-11) as second-line chemotherapy after 5FU failure. CPT-11 F205, F220, F221 and V222 study groups. Br J Cancer 83:431–437PubMedCrossRef

Sargent DJ, Kohne CH, Sanoff HK et al (2009) Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 27:1948–1955PubMedCrossRef

Amado RG, Wolf M, Peeters M et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634PubMedCrossRef

Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408–1417PubMedCrossRef

10.

Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3–15PubMedCrossRef

11.

Kaplan DH, Shankaran V, Dighe AS et al (1998) Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95:7556–7561PubMedCrossRef

12.

Shankaran V, Ikeda H, Bruce AT et al (2001) IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410:1107–1111PubMedCrossRef

13.

Pages F, Berger A, Camus M et al (2005) Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353:2654–2666PubMedCrossRef

14.

Galon J, Costes A, Sanchez-Cabo F et al (2006) Type, density and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:1960–1964PubMedCrossRef

15.

Ohtani H (2007) Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human colorectal cancer. Cancer Immun 7:4PubMed

16.

Atreya I, Neurath MF (2008) Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies. Expert Rev Anticancer Ther 8:561–572PubMedCrossRef

17.

Riesco A (1970) Five-year cancer cure: relation to total amount of peripheral lymphocytes and neutrophils. Cancer 25:135–140PubMedCrossRef

18.

Ownby HE, Roi LD, Isenberg RR, Brennan MJ (1983) Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 52:126–130PubMedCrossRef

19.

Hasenclever D, Diehl V (1998) A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N Engl J Med 339:1506–1514PubMedCrossRef

20.

Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas and lymphomas. Cancer Res 69:5383–5391PubMedCrossRef

21.

Ray-Coquard I, Ghesquiere H, Bachelot T et al (2001) Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas. Br J Cancer 85:816–822PubMedCrossRef

22.

Ray-Coquard I, Borg C, Bachelot T et al (2003) Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy. Br J Cancer 88:181–186PubMedCrossRef

23.

Alexandre J, Rey E, Girre V et al (2007) Relationship between cytochrome 3A activity, inflammatory status and the risk of docetaxel-induced febrile neutropenia: a prospective study. Ann Oncol 18:168–172PubMedCrossRef

24.

Blay JY, Le Cesne A, Mermet C et al (1998) A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood 92:405–410PubMed

25.

Ray-Coquard I, Le Cesne A, Rubio MT et al (1999) Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 study group. J Clin Oncol 17:2840–2846PubMed

26.

Lissoni P, Brivio F, Fumagalli L et al (2004) Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Mark 19:135–140

27.

Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, National cancer institute of the United States, National cancer institute of Canada. J Natl Cancer Inst 92:205–216PubMedCrossRef

28.

Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observation. J Am Stat Assoc 53:457–481CrossRef

29.

Cox DR (1972) Regression models and life-tables. J R Stat Soc 34(Ser B):187–220

30.

Lissoni P, Fumagalli L, Paolorossi F, Mandala M (1999) Changes in lymphocyte number during cancer chemotherapy and their relation to clinical response. Int J Biol Mark 14:115–117

31.

Maltoni M, Pirovano M, Nanni O et al (1997) Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian multicenter study group on palliative care. J Pain Symp Manag 13:1–9CrossRef

32.

Lissoni P, Brivio F, Fumagalli L et al (2005) Enhancement of the efficacy of chemotherapy with oxaliplatin plus 5-fluorouracil by pretreatment with IL-2 subcutaneous immunotherapy in metastatic colorectal cancer patients with lymphocytopenia prior to therapy. In Vivo 19:1077–1080PubMed

33.

Saito T, Kuss I, Dworacki G et al (1999) Spontaneous ex vivo apoptosis of peripheral blood mononuclear cells in patients with head and neck cancer. Clin Cancer Res 5:1263–1273PubMed

34.

Dworacki G, Meidenbauer N, Kuss I et al (2001) Decreased zeta chain expression and apoptosis in CD3+ peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 7:947s–957sPubMed

35.

Goldrath AW, Bevan MJ (1999) Selecting and maintaining a diverse T-cell repertoire. Nature 402:255–262PubMedCrossRef

36.

Blay JY, Negrier S, Combaret V et al (1992) Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52:3317–3322PubMed

37.

Aggarwal S, Gollapudi S, Gupta S (1999) Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J Immunol 162:2154–2161PubMed

38.

Borg C, Ray-Coquard I, Philip I et al (2004) CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer. Cancer 101:2675–2680PubMedCrossRef

39.

Jansman FG, Sleijfer DT, Coenen JL et al (2000) Risk factors determining chemotherapeutic toxicity in patients with advanced colorectal cancer. Drug Saf 23:255–278PubMedCrossRef

40.

Blay JY, Chauvin F, Le Cesne A et al (1996) Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia. J Clin Oncol 14:636–643PubMed

41.

Hoffmann TK, Dworacki G, Tsukihiro T et al (2002) Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res 8:2553–2562PubMed

42.

Mitry E, Douillard JY, Van Cutsem E et al (2004) Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials. Ann Oncol 15:1013–1017PubMedCrossRef

43.

Meguid RA, Slidell MB, Wolfgang CL et al (2008) Is there a difference in survival between right versus left-sided colon cancers? Ann Surg Oncol 15:2388–2394PubMedCrossRef

44.

Rosenberg SA, Sportes C, Ahmadzadeh M et al (2006) IL-7 administration to humans leads to expansion of CD8+ and CD4+ cells but a relative decrease of CD4+ T-regulatory cells. J Immunother 29:313–319PubMedCrossRef

45.

Zhang H, Chua KS, Guimond M et al (2005) Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+ CD25+ regulatory T cells. Nat Med 11:1238–1243PubMedCrossRef

Title: Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy
Authors: N. Cézé
G. Thibault
G. Goujon
J. Viguier
H. Watier
E. Dorval
T. Lecomte
Publication date: 01-11-2011
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 5/2011
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-011-1610-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2011

A novel method for quantification of gemcitabine and its metabolites 2′,2′-difluorodeoxyuridine and gemcitabine triphosphate in tumour tissue by LC–MS/MS: comparison with 19F NMR spectroscopy

Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function

Accumulation and distribution of doxorubicin in tumour spheroids: the influence of acidity and expression of P-glycoprotein

Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells

A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy

Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer